Company intelligence / Profile preview

Intellect Neurosciences, Inc.

Englewood Cliffs, New Jersey, USAadcreview.com ↗

Ownership: Private
Development stage: Phase 1

Overview

OX1 has demonstrated safety in human Phase I trials for Friedreich’s Ataxia and potentially other neurodegenerative conditions. Other pipeline assets are at preclinical or pending clinical trial stages targeting Alzheimer’s disease and retinal/neurodegenerative disorders.[1]

Therapeutic areas: OphthalmologyNeurology
Modalities: Small moleculesMonoclonal antibodies (mAbs)Antibody-drug conjugates (ADCs)Therapeutic vaccines
Industry: Biotech

Drug pipeline

5 assets

indole-3-propionic acid

4 more assets in the full pipeline.

Request access →

Partnerships

Medical Research Council TechnologySouth Alabama Medical Science FoundationNew York UniversityAHP Manufacturing BVNorthwestern University

Beyond the preview

Go deeper on Intellect Neurosciences, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Intellect Neurosciences, Inc..

Explore the full profile